



RxAir360

RxAir360, Inc.

Unaudited Financial Statements

For the Year Ended December 31, 2023

Basis of Accounting: Accrual — U.S. GAAP

Report Type: Unaudited — Management Prepared

Prepared in connection with OTC Markets / FINRA Form 211

Date Prepared: September 13, 2026

These replacement financial statements reflect the Company's updated accounting records and capitalization reconciliation for the periods presented.

RxAir360, Inc.**Balance Sheet**

As of December 31, 2023

ASSETS	
Cash and cash equivalents	\$78,411.26
Intangible assets — Patents/IP	\$3,000,000.00
Total Assets	\$3,078,411.26
LIABILITIES	
Note payable — inventor	\$2,620,825.00
Total Liabilities	\$2,620,825.00
STOCKHOLDERS' EQUITY	
Preferred stock	\$10.88
Additional paid-in capital	\$1,085,439.12
Equity adjustment clearing	(\$6,500.00)
Retained earnings / accumulated deficit	(\$160,293.88)
Net loss — current year	(\$464,807.09)
Total Stockholders' Equity	\$457,586.26
Total Liabilities and Equity	\$3,078,411.26

RxAir360, Inc.
Statement of Operations
For the Year Ended December 31, 2023

REVENUES	
Total revenues	\$0.00
OPERATING EXPENSES	
Consulting services	\$428,530.00
Legal fees	\$400.90
Travel expenses	\$6,863.19
Office expenses	\$6,435.04
Advertising & marketing	\$1,402.00
Investor referral fees	\$7,050.00
Supplies & materials	\$10,000.00
Meals & entertainment	\$1,537.09
Startup compliance	\$999.00
General business expenses	\$357.00
Website & email costs	\$797.22
Phone & utilities	\$43.80
Fraud loss — non-recoverable	\$100.00
Accounting fees	\$165.00
Total Operating Expenses	\$464,680.24
Other income	\$0.08
Other expense — vehicle	(\$126.93)
NET LOSS	(\$464,807.09)

RxAir360, Inc.
Statement of Cash Flows
For the Year Ended December 31, 2023

OPERATING ACTIVITIES	
Net loss	(\$464,807.09)
Net cash used in operating activities	(\$464,807.09)
INVESTING ACTIVITIES	
Net cash used in investing activities	\$0.00
FINANCING ACTIVITIES	
Proceeds from issuance of preferred stock	\$626,335.70
Equity adjustment clearing	(\$6,500.00)
Founder contributions	\$3,614.06
Note payable — inventor principal payments	(\$131,875.00)
Net cash provided by financing activities	\$491,574.76
NET CHANGE IN CASH	\$26,767.67
Cash — beginning of period	\$51,643.59
Cash — end of period	\$78,411.26

RxAir360, Inc.
Statement of Changes in Stockholders' Equity
For the Year Ended December 31, 2023

	Preferred Stock	APIC	Equity Adj.	Accum. Deficit	Total
Balance, Dec. 31, 2022					\$298,545.82
Net loss — 2023				(\$464,807.09)	(\$464,807.09)
Net capital/equity activity					\$623,847.53
Balance, Dec. 31, 2023	\$10.88	\$1,085,439.12	(\$6,500.00)	(\$625,100.97)	\$457,586.26

RxAir360, Inc.

Notes to Unaudited Financial Statements

As of and for the period ended December 31, 2023

NOTE 1 — ORGANIZATION AND NATURE OF OPERATIONS

RxAir360, Inc. (the "Company") is a Delaware corporation formed in 2022 to develop and commercialize a compact vertical monoplace hyperbaric oxygen therapy chamber for physician-office and outpatient clinical environments. The Company is in the pre-commercial stage and is focused on product engineering, regulatory preparation, capital formation and commercialization readiness.

NOTE 2 — BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES

These financial statements are management-prepared and unaudited and are presented on the accrual basis of accounting in accordance with U.S. generally accepted accounting principles. Cash and cash equivalents consist of demand deposits. The Company has not recognized commercial revenue from its core HBOT platform.

NOTE 3 — INTANGIBLE ASSETS AND NOTE PAYABLE — INVENTOR

The Company records its patent and intellectual-property rights at a contracted assignment value of \$3,000,000 pursuant to the October 1, 2022 IP Assignment and Reimbursement Agreement. The related inventor obligation is presented separately as a long-term liability. The Company has not commenced amortization of the recorded patent/IP asset.

RELATED-PARTY TRANSACTIONS

The founder has made contributions to support Company operations. The balance sheet separately presents the inventor reimbursement obligation. The "Due to Related Party - Founder" balance was \$0.00 at the 2025 year-end and 2026 interim reporting dates presented in the updated accounting records.

EQUITY STRUCTURE

The Company has financed operations through preferred-stock offerings, founder contributions and other equity transactions. Preferred stock is stated at \$0.00001 par value based on shares issued, and the excess of credited offering consideration over par value is presented as additional paid-in capital (APIC). Final preferred-offering controls are: Series Pre-Seed, 4,245,000 shares and \$424,500.00 consideration; Series A-1, 10,551,559 shares and \$1,055,155.82 consideration; and Series A, 6,306,497 shares and \$945,972.81 consideration. Dynamic Stock Transfer serves as transfer agent.

GOING CONCERN

The Company has incurred recurring losses, has not yet commenced commercial sales of its core product, and requires additional capital to execute its operating plan. These conditions raise substantial doubt about the Company's ability to continue as a going concern. Management's plans include continued capital formation, completion of the FDA regulatory pathway, commercialization following required clearance, and development of additional financing sources. There can be no assurance that these plans will be successful.

COMMITMENTS AND CONTINGENCIES

Management is not aware of material legal proceedings requiring accrual in these management-prepared financial statements. The Company continues to incur costs related to regulatory testing, professional services, engineering and commercialization preparation.

SUBSEQUENT EVENTS

Management evaluated subsequent events through September 13, 2026, the date these replacement financial statements were prepared. Subsequent financing and operating activity is not reflected in the period-end balances unless it relates to conditions existing at the reporting date.

Management statement: These financial statements are unaudited and have not been audited or reviewed by an independent certified public accountant. No CPA assurance is expressed.